Genzyme Corp. has launched a phase 3 trial for a Gaucher disease drug candidate that could treat some patients now affected by the company’s shortage of Cerezyme. The company’s drug candidate, Genz-112638, is a potential new oral therapy for Type 1 Gaucher disease.

Last Modified: Tuesday, October 20th, 2009 @ 20:59

This entry was posted on Tuesday, October 20th, 2009 at 8:59 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.